Associations of TACSTD2/ TROP2 and NECTIN‐4/ NECTIN ‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts

Abstract excerpt

AIMS: Treatment options for advanced urothelial carcinoma (aUC) rapidly evolved: besides immunomodulative therapeutic options and inhibitors targeting Fibroblast growth factor receptor (FGFR) alterations, two new antibody-drug conjugates (ADC), sacituzumab govitecan (SG) and enfortumab vedotin (EV), have been approved. However, little is known about the associations of specific aUC properties and the surface...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bladder and Urothelial Cancer Treatments
• Share to Fibroblast Growth Factor Research
• Share to Urinary and Genital Oncology Studies